Compounds that are ERK inhibitors

US9226922B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Kevin J. Wilson · Boston, US
• David J. Witter · Norfolk, US
• Matthew H. Daniels · Somerville, US
• Angie R. Angeles · Boston, US
• Phieng Siliphaivanh · Newton, US
• David L. Sloman · Brookline, US
• Brendan M. O'Boyle · Boston, US
• Danielle Falcone · Brookline, US
• Catherine White · Newton, US
• Ron Ferguson · Scotch Plains, US
• Wei Zhou · Scotch Plains, US
• Kathryn Lipford · Boston, US
• Umar Faruk Mansoor · Framingham, US
• Salem Fevrier · Cranford, US
• Xianhai Huang · Hackettstown, US
• Ravi Kurukulasuriya · Gurnee, US
• Judson E. Richard · Kittery, US
• Shuyi Tang · Shanghai, CN
• Christopher W. Boyce · Flemington, US
• Joseph A. Kozlowski · Princeton, US
• Raman K. Bakshi · Edison, US
• Ganesh Babu Karunakaran · Bengaluru, IN

Key dates

• Filing date: Sep 26, 2013
• Grant date: Jan 5, 2016
• Expiry date: Sep 26, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).